Drugs / NY105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05691881 | Sep 2022 → Mar 2023 | cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05691881 ↗ |
| Route | Intravenous | “20-40mcg, IV” NCT05691881 ↗ |